XML 33 R10.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Revenues | 12 Months Ended
--- | ---
Dec. 31, 2019
Revenue from Contract with Customer [Abstract] |
Revenue from Contract with Customer [Text Block] | REVENUES Disaggregation of Revenues The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):
|  | Year Ended December 31, 2019 |  | Year Ended December 31, 2018 |  | Year Ended December 31, 2017(6)
|  | U.S. |  | Europe |  | Other International |  | Total |  | U.S. |  | Europe |  | Other International |  | Total |  | U.S. |  | Europe |  | Other International |  | Total
Product Sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atripla |  | $ | 501 |  |  | $ | 60 |  |  | $ | 39 |  |  | $ | 600 |  |  | $ | 967 |  |  | $ | 131 |  |  | $ | 108 |  |  | $ | 1,206 |  |  | $ | 1,288 |  |  | $ | 335 |  |  | $ | 183 |  |  | $ | 1,806 |
Biktarvy |  | 4,225 |  |  | 370 |  |  | 143 |  |  | 4,738 |  |  | 1,144 |  |  | 39 |  |  | 1 |  |  | 1,184 |  |  | — |  |  | — |  |  | — |  |  | — |
Complera/Eviplera |  | 160 |  |  | 214 |  |  | 32 |  |  | 406 |  |  | 276 |  |  | 327 |  |  | 50 |  |  | 653 |  |  | 406 |  |  | 503 |  |  | 57 |  |  | 966 |
Descovy |  | 1,078 |  |  | 255 |  |  | 167 |  |  | 1,500 |  |  | 1,217 |  |  | 308 |  |  | 56 |  |  | 1,581 |  |  | 958 |  |  | 226 |  |  | 34 |  |  | 1,218 |
Genvoya |  | 2,984 |  |  | 664 |  |  | 283 |  |  | 3,931 |  |  | 3,631 |  |  | 794 |  |  | 199 |  |  | 4,624 |  |  | 3,033 |  |  | 534 |  |  | 107 |  |  | 3,674 |
Odefsey |  | 1,180 |  |  | 438 |  |  | 37 |  |  | 1,655 |  |  | 1,242 |  |  | 335 |  |  | 21 |  |  | 1,598 |  |  | 964 |  |  | 132 |  |  | 10 |  |  | 1,106 |
Stribild |  | 268 |  |  | 75 |  |  | 26 |  |  | 369 |  |  | 505 |  |  | 97 |  |  | 42 |  |  | 644 |  |  | 811 |  |  | 195 |  |  | 47 |  |  | 1,053 |
Truvada |  | 2,640 |  |  | 101 |  |  | 72 |  |  | 2,813 |  |  | 2,605 |  |  | 260 |  |  | 132 |  |  | 2,997 |  |  | 2,266 |  |  | 644 |  |  | 224 |  |  | 3,134 |
Other HIV(1) |  | 30 |  |  | 5 |  |  | 12 |  |  | 47 |  |  | 40 |  |  | 7 |  |  | 14 |  |  | 61 |  |  | 43 |  |  | 6 |  |  | 9 |  |  | 58 |
Revenue share – Symtuza(2) |  | 249 |  |  | 130 |  |  | — |  |  | 379 |  |  | 27 |  |  | 52 |  |  | — |  |  | 79 |  |  | — |  |  | — |  |  | — |  |  | — |
AmBisome |  | 37 |  |  | 234 |  |  | 136 |  |  | 407 |  |  | 46 |  |  | 229 |  |  | 145 |  |  | 420 |  |  | 28 |  |  | 207 |  |  | 131 |  |  | 366 |
Ledipasvir/Sofosbuvir(3) |  | 312 |  |  | 71 |  |  | 260 |  |  | 643 |  |  | 802 |  |  | 144 |  |  | 276 |  |  | 1,222 |  |  | 3,053 |  |  | 704 |  |  | 613 |  |  | 4,370 |
Letairis |  | 618 |  |  | — |  |  | — |  |  | 618 |  |  | 943 |  |  | — |  |  | — |  |  | 943 |  |  | 887 |  |  | — |  |  | — |  |  | 887 |
Ranexa |  | 216 |  |  | — |  |  | — |  |  | 216 |  |  | 758 |  |  | — |  |  | — |  |  | 758 |  |  | 717 |  |  | — |  |  | — |  |  | 717 |
Sofosbuvir/Velpatasvir(4) |  | 971 |  |  | 553 |  |  | 441 |  |  | 1,965 |  |  | 934 |  |  | 654 |  |  | 378 |  |  | 1,966 |  |  | 2,404 |  |  | 869 |  |  | 237 |  |  | 3,510 |
Vemlidy |  | 309 |  |  | 21 |  |  | 158 |  |  | 488 |  |  | 245 |  |  | 12 |  |  | 64 |  |  | 321 |  |  | 111 |  |  | 5 |  |  | 6 |  |  | 122 |
Viread |  | 32 |  |  | 69 |  |  | 142 |  |  | 243 |  |  | 50 |  |  | 82 |  |  | 175 |  |  | 307 |  |  | 514 |  |  | 238 |  |  | 294 |  |  | 1,046 |
Vosevi |  | 178 |  |  | 54 |  |  | 25 |  |  | 257 |  |  | 304 |  |  | 78 |  |  | 14 |  |  | 396 |  |  | 267 |  |  | 22 |  |  | 4 |  |  | 293 |
Yescarta |  | 373 |  |  | 83 |  |  | — |  |  | 456 |  |  | 263 |  |  | 1 |  |  | — |  |  | 264 |  |  | 7 |  |  | — |  |  | — |  |  | 7 |
Zydelig |  | 47 |  |  | 54 |  |  | 2 |  |  | 103 |  |  | 61 |  |  | 70 |  |  | 2 |  |  | 133 |  |  | 69 |  |  | 77 |  |  | 3 |  |  | 149 |
Other(5) |  | 157 |  |  | 116 |  |  | 12 |  |  | 285 |  |  | 137 |  |  | 76 |  |  | 107 |  |  | 320 |  |  | 283 |  |  | 314 |  |  | 583 |  |  | 1,180 |
Total product sales |  | 16,565 |  |  | 3,567 |  |  | 1,987 |  |  | 22,119 |  |  | 16,197 |  |  | 3,696 |  |  | 1,784 |  |  | 21,677 |  |  | 18,109 |  |  | 5,011 |  |  | 2,542 |  |  | 25,662 |
Royalty, contract and other revenues |  | 80 |  |  | 244 |  |  | 6 |  |  | 330 |  |  | 72 |  |  | 310 |  |  | 68 |  |  | 450 |  |  | 85 |  |  | 300 |  |  | 60 |  |  | 445 |
Total revenues |  | $ | 16,645 |  |  | $ | 3,811 |  |  | $ | 1,993 |  |  | $ | 22,449 |  |  | $ | 16,269 |  |  | $ | 4,006 |  |  | $ | 1,852 |  |  | $ | 22,127 |  |  | $ | 18,194 |  |  | $ | 5,311 |  |  | $ | 2,602 |  |  | $ | 26,107 |
_________________________________________
(1) | Includes Emtriva and Tybost.
(2) | Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC (Janssen).
(3) | Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.
(4) | Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.
(5) | Includes Cayston, Hepsera and Sovaldi.
(6) | The information for the year ended December 31, 2017 has not been adjusted in accordance with our modified retrospective adoption of Topic 606 and continues to be reported in accordance with our historical accounting under Topic 605.
Revenues Recognized from Performance Obligations Satisfied in Prior Periods Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $741 million and $541 million for the years ended December 31, 2019 and 2018, respectively. Changes in estimates for variable consideration related to sales made in prior years resulted in a $257 million increase and a $56 million decrease in revenues for the years ended December 31, 2019 and 2018, respectively. Contract Balances Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $144 million and $125 million as of December 31, 2019 and 2018, respectively. Contract liabilities were not material as of December 31, 2019 and 2018.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration